Investors never know what to expect for Amedisys
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Amedisys with 10 of 13 analysts rating it hold. Analysts don't like Amedisys as much as competitor Gentiva Health Services overall. Three out of 10 analysts rate Gentiva Health Services a buy compared to two of 13 for Amedisys. While analysts still rate the stock a hold, they are a little more optimistic about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $383.3 million in revenue this quarter. That would represent a decline of 9.2% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.70 per share. Estimates range from $0.54 to $0.76.
What our community says:
CAPS All Stars are solidly backing the stock, with 87.5% granting it an "outperform" rating. The community at large agrees with the All Stars, with 90.3% assigning it a rating of "outperform." Fools are bullish on Amedisys and haven't been shy with their opinions lately, logging 348 posts in the past 30 days. Amedisys' bearish CAPS rating of two out of five stars falls short of the Fool community sentiment.
Amedisys' income has fallen year over year by an average of 37%. Revenue has fallen in the past two quarters. The company's gross margin shrank by 3.1 percentage points in the last quarter. Revenue fell 11.8% while cost of sales fell 6.3% to $191.2 million from a year earlier.
One final thing: If you want to keep tabs on Amedisys movements, and for more analysis on the company, make sure you add it to your Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.